Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis.

acute renal injury atrial fibrillation catheter ablation hemolysis pulsed field ablation

Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
30 Aug 2024
Historique:
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

Pulsed field ablation (PFA) is increasingly used in clinical practice for the treatment of atrial fibrillation. While the susceptibility of erythrocytes to electroporation is well established, the effect of cardiac PFA technologies on hemolysis has remained underreported. The aim of this study was to investigate the incidence, severity, and clinical impact of PFA-induced hemolysis. We included n=145 patients undergoing atrial fibrillation catheter ablation with a pentaspline PFA catheter (biphasic, bipolar pulses of 2 kV) and n=70 patients receiving radiofrequency ablation (40-90 W) at 4 high-volume European centers. The lesion set comprised pulmonary vein isolation for paroxysmal atrial fibrillation and pulmonary vein isolation±additional lesions for persistent atrial fibrillation. Hemolysis and renal function biomarkers were analyzed in blood samples at baseline, at the end of ablation, and 24 hours after the procedure. Baseline characteristics were well balanced between groups (overall mean, 65.7±9.4 years; 69.3% male). The ablation procedures comprised a mean of 61.6±27.4 PFA deliveries and 26.3±15.0 minute RF duration. Hemolysis was detected in 94.3% versus 6.8% of patients after PFA versus radiofrequency ablation ( Intravascular hemolysis is a frequent finding after PFA and increases with the number of PFA deliveries. Until the clinical impact of PFA-associated hemolysis is fully elucidated, a careful titration of PFA deliveries during the ablation procedure is warranted.

Sections du résumé

BACKGROUND UNASSIGNED
Pulsed field ablation (PFA) is increasingly used in clinical practice for the treatment of atrial fibrillation. While the susceptibility of erythrocytes to electroporation is well established, the effect of cardiac PFA technologies on hemolysis has remained underreported. The aim of this study was to investigate the incidence, severity, and clinical impact of PFA-induced hemolysis.
METHODS UNASSIGNED
We included n=145 patients undergoing atrial fibrillation catheter ablation with a pentaspline PFA catheter (biphasic, bipolar pulses of 2 kV) and n=70 patients receiving radiofrequency ablation (40-90 W) at 4 high-volume European centers. The lesion set comprised pulmonary vein isolation for paroxysmal atrial fibrillation and pulmonary vein isolation±additional lesions for persistent atrial fibrillation. Hemolysis and renal function biomarkers were analyzed in blood samples at baseline, at the end of ablation, and 24 hours after the procedure.
RESULTS UNASSIGNED
Baseline characteristics were well balanced between groups (overall mean, 65.7±9.4 years; 69.3% male). The ablation procedures comprised a mean of 61.6±27.4 PFA deliveries and 26.3±15.0 minute RF duration. Hemolysis was detected in 94.3% versus 6.8% of patients after PFA versus radiofrequency ablation (
CONCLUSIONS UNASSIGNED
Intravascular hemolysis is a frequent finding after PFA and increases with the number of PFA deliveries. Until the clinical impact of PFA-associated hemolysis is fully elucidated, a careful titration of PFA deliveries during the ablation procedure is warranted.

Identifiants

pubmed: 39212069
doi: 10.1161/CIRCEP.124.012732
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012732

Auteurs

Miruna A Popa (MA)

Department of Cardiac Pacing and Electrophysiology, Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux (M.A.P., F. Sacher, N.D., M.H., P.J.).
Department of Electrophysiology, German Heart Centre Munich (M.A.P.).

Sandrine Venier (S)

Technical University of Munich, Germany. University Hospital of Grenoble Alpes (S.V., P.D.).

Roberto Menè (R)

Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France (R.M., S.C., J.-P.A., F. Saitta, S.B.).

Domenico Della Rocca (D)

Universiteit Ziekenhuis, Vrije Universiteit Brussel (VUB), Jette Brussels, Belgium (D.D.R., G.-B.C., C.d.A., S.B.).

Frédéric Sacher (F)

Department of Cardiac Pacing and Electrophysiology, Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux (M.A.P., F. Sacher, N.D., M.H., P.J.).
IHU LIRYC, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université and INSERM-U1045, University of Bordeaux, France (F. Sacher, N.D., M.H., G.C., P.J.).

Nicolas Derval (N)

Department of Cardiac Pacing and Electrophysiology, Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux (M.A.P., F. Sacher, N.D., M.H., P.J.).
IHU LIRYC, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université and INSERM-U1045, University of Bordeaux, France (F. Sacher, N.D., M.H., G.C., P.J.).

Mélèze Hocini (M)

Department of Cardiac Pacing and Electrophysiology, Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux (M.A.P., F. Sacher, N.D., M.H., P.J.).
IHU LIRYC, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université and INSERM-U1045, University of Bordeaux, France (F. Sacher, N.D., M.H., G.C., P.J.).

Stéphanie Dulucq (S)

Laboratory of Hematology, CHU Bordeaux and University of Bordeaux, Inserm, UMR1312, BRIC, Bordeaux Institute of Oncology, France (S.D.).

Guido Caluori (G)

IHU LIRYC, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université and INSERM-U1045, University of Bordeaux, France (F. Sacher, N.D., M.H., G.C., P.J.).

Stéphane Combes (S)

Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France (R.M., S.C., J.-P.A., F. Saitta, S.B.).

Jean-Paul Albenque (JP)

Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France (R.M., S.C., J.-P.A., F. Saitta, S.B.).

Federica Saitta (F)

Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France (R.M., S.C., J.-P.A., F. Saitta, S.B.).

Bernhard Haller (B)

TUM School of Medicine and Health, Institute of AI and Informatics in Medicine (B.H.).

Gian-Battista Chierchia (GB)

Universiteit Ziekenhuis, Vrije Universiteit Brussel (VUB), Jette Brussels, Belgium (D.D.R., G.-B.C., C.d.A., S.B.).

Carlo de Asmundis (C)

Universiteit Ziekenhuis, Vrije Universiteit Brussel (VUB), Jette Brussels, Belgium (D.D.R., G.-B.C., C.d.A., S.B.).

Pascal Defaye (P)

Technical University of Munich, Germany. University Hospital of Grenoble Alpes (S.V., P.D.).

Serge Boveda (S)

Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France (R.M., S.C., J.-P.A., F. Saitta, S.B.).
Universiteit Ziekenhuis, Vrije Universiteit Brussel (VUB), Jette Brussels, Belgium (D.D.R., G.-B.C., C.d.A., S.B.).

Pierre Jaïs (P)

Department of Cardiac Pacing and Electrophysiology, Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux (M.A.P., F. Sacher, N.D., M.H., P.J.).
IHU LIRYC, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université and INSERM-U1045, University of Bordeaux, France (F. Sacher, N.D., M.H., G.C., P.J.).

Classifications MeSH